Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED has completed patient enrollment for the SAFFRON Phase III trial, which investigates the combination of ORPATHYS® and TAGRISSO® as a treatment for NSCLC patients with MET overexpression after progression on TAGRISSO®. This trial could potentially lead to global regulatory filings if results are favorable, marking a significant step in offering a chemotherapy-free treatment option for lung cancer patients.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited operates in the pharmaceutical industry, focusing on the development and commercialization of targeted therapies for cancer treatment. The company collaborates with AstraZeneca to develop ORPATHYS®, a selective MET tyrosine kinase inhibitor, and TAGRISSO®, an EGFR tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) patients.
Average Trading Volume: 9,903,414
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$20.72B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.